Ghidul pentru managementul hipertensiunii arteriale 2007 Grupul ...

Ghidul pentru managementul hipertensiunii arteriale 2007Ghid al Societăţii Europene de Cardiologie625. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD,Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronicheart failure and high-risk acute myocardial infarction. Ann InternMed 2004; 141:693-704. MA.626. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ,Michelson EL, Olofsson B, Ostergren J. CHARM Investigators Committees.Effects of candesartan in patients with chronic heart failure andpreserved left-ventricular ejection fraction: the CHARM-PreservedTrial. Lancet 2003;362:777-781.627. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence,prognosis, and predisposing conditions for atrial fibrillation: population-basedestimates. Am J Cardiol 1998;82:2N-9N. OS.628. Hankey GJ. Preventable stroke and stroke prevention. J ThrombHaemost 2005;3:1638-1645. RV.629. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulatedpatients with atrial fibrillation. Eur Heart J 2007;28:752-759. OS.630. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S,Connolly SJ. Prevention of atrial fibrillation with angiotensin-convertingenzyme inhibitors and angiotensin receptor blockers: a metaanalysis.J Am Coll Cardiol 2005;45:1832-1839. MA.631. Perera GA. Hypertensive vascular disease: description and naturalhistory. J Chronic Dis 1955;1:33-42.632. Redon J, Rovira E, MirallesA, Julve R, Pascual JM. Factors related tothe occurrence of microalbuminuria during antihypertensive treatmentin essential hypertension. Hypertension 2002;39:794-798. OS.633. Lawes CMM, Vander Hoorn S, Law MR, Elliott P, MacMahon S,Rodgers A. Blood pressure and the global burden of disease 2000. PartI: Estimates of blood pressure levels. J Hypertens 2006; 24:413-422.OS.634. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, KannelWB, Levy D. Hemodynamic patterns of age-related changes in bloodpressure. The Framingham Heart Study. Circulation 1997;96:308-315.OS.635. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction inadults (the Framingham Heart Study). Am J Cardiol 1987;59:91G-94G. RV.636. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, WeberM, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieslinski A,Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP,Siamo poulos KC, Storset O. Outcomes in subgroups of hypertensivepatients treated with regimens based on valsartan and amlodipine: Ananalysis of findings from the VALUE trial. J Hypertens 2006;24:2163-2168. CT.637. Dong W, Colhoun HM, Poulter NR. Blood pressure in women usingoral contraceptives results from the Health Survey for England 1994.J Hypertens 1997;15:1063-1068. OS.638. Chasan-Taber L, Willett WC, Manson JAE, Spiegelman D, HunterDJ, Curhan G, Colditz GA, Stampfer MJ. Prospective study of oralcontraceptives and hypertension among women in the United States.Circulation 1996; 94:483-489. OS.639. Lip GY, Beevers M, Beevers DG. Malignant hypertension in youngwomen is related to previous hypertension in pregnancy, not oralcontra ception. Quart J Med 1997;90:571-575. OS.640. Woods JW. Oral contraceptives and hypertension. Hypertension1998;11:II11-II15. RV.641. Kawano H, Motoyama T, Kugiyama K, Hirashima O, Ohgushi M,Fujii H, Ogawa H, Yasue H. Gender difference in improvement ofendothelium-dependent vasodilation after estrogen supplementation.J Am Coll Cardiol 1997;30:914-919. OS.642. Skinner SL, Lumbers ER, Symonds EM. Alteration by oral contraceptivesof normal menstrual changes in plasma renin activity, concentrationand substrate. Clin Sci 1969; 36:67-76. OS.643. Giannattasio C, Failla M, Grappiolo A, Stella ML, Del Bo A, ColomboM, Mancia G. Fluctuations of radial artery distensibility throughoutthe menstrual cycle. Arterioscler Thromb Vasc Biol 1999;19:1925-1929.644. Ribstein J, Halimi J-M, Guilhem du Cailar, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users.Hypertension 1999;33:90-95.Revista Română de CardiologieVol. XXII, Nr. 3, 2007645. Inman WHW, Vessey MP. Investigation of deaths from pulmonary,coronary, and cerebral thrombosis and embolism in women of childbearingage. BMJ 1968;2:193-199. OS.646. Vessey MP, Doll R. Investigation of the relation between use of oralcon tra ceptives and thromboembolic disease. BMJ 1968; 2:199-205.OS.647. Masi AT, Dudgate M. Cerebrovascular disease associated with theuse of oral contraceptives: a review of the English-language literature.Ann InternMed 1970;72:111-121. RV.648. Han W-S, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, GinsbergJS. Risk of stroke in women exposed to low-dose oral contraceptives.A critical evaluation of the evidence. Arch Intern Med 2004; 164:741-747. MA.649. Curtis KM, Mohllajee AP, Martins SL, Peterson HB. Combined oral contraceptive use among women with hypertension: a systematic review.Contraception 2006;73:179-188. MA.650. Gomes MP, Deitcher SR. Risk of venous thromboembolic diseaseassociated with hormonal contraceptives and hormone replacementtherapy. Arch Intern Med 2004; 164:1965-1976. OS.651. Hussain SF. Progestogen-only pills and high blood pressure: is therean association? A literature review. Contraception 2004;69:89-97. RV.652. Zanchetti A, Facchetti R, Cesana GC, Modena GM, Pirrelli A, SegaR. Menopause-related blood pressure increase and its relationshipto age and body mass index: the SIMONA epidemiological study. JHypertens 2005;23:2269-2276. OS.653. Shelley JM, Green A, Smith AM, Dudley E, Dennerstein L, Hopper J,Burger H. Relationship of sex hormones to lipids and blood pressurein mid-aged women. Ann Epidemiol 1998;8:39-45. OS.654. Grobbee DE, Van Hemert AM, Vanderbroucke JP, Hofman A,Valkenburg HA. Importance of body weight in determining risk andlevel of blood pressure in postmenopausal women. J Hypertens 1988;6(Suppl):S614-S616. OS.655. Staessen JA, Ginocchio G, Thijs L, Fagard R. Conventional and ambulatoryblood pressure and menopause in a prospective populationstudy. J Hum Hypertens 1997; 11:507-514. OS.656. Casiglia E, d’Este D, Ginocchio G, Colangeli G, Onesto C, TramontinP, Ambrosio GB, Pessina AC. Lack of influence of menopause onblood pressure and cardiovascular risk profile: a 16 year longitudinalstudy concerning a cohort of 568 women. J Hypertens 1996;14:729-736. OS.657. Lindqvist O, Bengtsson C. Serum lipids arterial blood pressure bodyweight in relation to the menopause: results from a population studyof women in Goteborg Sweden. Scand J Clin Invest 1980;40:629-636.OS.658. Torng PL, Su TC, Sung FG, Chien KL, Huang SC, Chon SN, Lee YT.Effects of menopause on intraindividual changes in serum lipids,blood pressure and body weight: the Chin-Shan community cardiovascularcohort study. Atherosclerosis 2002; 161:409-415. OS.659. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausalwomen. The Postmenopausal Estrogen/Progestin Interventions(PEPI) Trial. JAMA 1995;273:199-208. RT.660. Grodstein F, Manson JE, Sampfer MJ. Postmenopausal hormone useand secondary prevention of coronary events in the nurses healthstudy, a prospective, observational study. Ann Intern Med 2001;135:18. OS.661. Falkenborn M, Persson I, Terent A, Adami HO, Lithell H, BergstromR. Hormone replacement therapy and the risk of stroke, follow-up of apopulation-based cohort in Sweden. Arch Intern Med 1993;153:1201-1209. OS.662. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreasedrisk of stroke among postmenopausal hormone users, results from anational cohort. Arch Intern Med 1993;153:73-79. OS.663. Scuteri A, Bos AJG, Brant LJ, Talbot L, Lakatta EG, Fleg JL. Hormonereplacement therapy and longitudinal changes in blood pressure inpostmenopausal women. Ann Intern Med 2001; 135:229-238. OS.664. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B,Vittinghoff E. Randomized trial of estrogen plus progestin for secondaryprevention of coronary heart disease in postmenopausal women.